The Incidence Mortality and Survival of Malignant Hematopoietic Neoplasms in the United States: A Surveillance, Epidemiology, and End Results (SEER) 2000-2022 Database Analysis
Author(s)
Vlad Zah, DPhil, Filip Stanicic, PhD (c), Dimitrije Grbic, PhD (c).
ZRx Outcomes Research, Inc., Mississauga, ON, Canada.
ZRx Outcomes Research, Inc., Mississauga, ON, Canada.
OBJECTIVES: Analyzing the disease burden of hematopoietic neoplasms (HN) in the US using the Surveillance, Epidemiology, and End Results (SEER) data (released April 2025).
METHODS: Data from 17 US cancer registries (2000-2022) were gathered and analyzed with SEER*Stat. The study population involved malignant HN patients. Outcomes included crude incidence and mortality rates (per 100,000 population) and survival rates (as percentages).
RESULTS: There were 970,230 HN patients, mostly with B-cell neoplasms (59.2%). Patients were mostly 65+ years old (56.9%), males (55.4%), non-Hispanic Whites (70.6%), married (51.6%), metropolitan county residents (87.9%), and had annual household income (AHI) of $65,000-$90,000 (47.0%). Total HN incidence rate was 51.1, with B-cell neoplasms as the most common subtype (30.3). Higher rates were reported among elderly (225.4), males (57.2), non-Hispanic Whites (66.4), non-metropolitan county residents (60.1), and <$40,000 AHI group (56.8). The annual percent change (APC) for HN incidence from 2000-2022 shows an increasing trend (1.2, p<0.05). The same trend was observed for all subgroups, except Hodgkin‘s lymphoma (APC -0.7, p<0.05). Total HN mortality rate was 28.0. The highest rates were reported for B-cell neoplasms (16.4), elderly (172.6), males (32.1), non-Hispanic Whites (38.1), non-metropolitan county residents (36.2), and <$40,000 AHI (36.8). An increasing HN mortality trend was observed (APC 4.0, p<0.05) and for all subtypes, except for precursor lymphoid neoplasms. 5-year HN survival was 58.7%. The lowest 5-year survival rates were observed for acute myeloid leukemias (26.2%), 90+ years (10.3%), males (57.4%), non-Hispanic Blacks (56.3%), widowed (34.5%), non-metropolitan residents (54.0%), and <$40,000 AHI (50.1%).
CONCLUSIONS: The study findings showed a high HN burden. Most HN subtypes demonstrated increasing incidence and mortality trends. The lowest 5-year survival was observed for acute myeloid leukemias, with survival chances of approximately 1 in 4 patients. These results should be a compelling reason to accelerate the discovery and approval of new treatments.
METHODS: Data from 17 US cancer registries (2000-2022) were gathered and analyzed with SEER*Stat. The study population involved malignant HN patients. Outcomes included crude incidence and mortality rates (per 100,000 population) and survival rates (as percentages).
RESULTS: There were 970,230 HN patients, mostly with B-cell neoplasms (59.2%). Patients were mostly 65+ years old (56.9%), males (55.4%), non-Hispanic Whites (70.6%), married (51.6%), metropolitan county residents (87.9%), and had annual household income (AHI) of $65,000-$90,000 (47.0%). Total HN incidence rate was 51.1, with B-cell neoplasms as the most common subtype (30.3). Higher rates were reported among elderly (225.4), males (57.2), non-Hispanic Whites (66.4), non-metropolitan county residents (60.1), and <$40,000 AHI group (56.8). The annual percent change (APC) for HN incidence from 2000-2022 shows an increasing trend (1.2, p<0.05). The same trend was observed for all subgroups, except Hodgkin‘s lymphoma (APC -0.7, p<0.05). Total HN mortality rate was 28.0. The highest rates were reported for B-cell neoplasms (16.4), elderly (172.6), males (32.1), non-Hispanic Whites (38.1), non-metropolitan county residents (36.2), and <$40,000 AHI (36.8). An increasing HN mortality trend was observed (APC 4.0, p<0.05) and for all subtypes, except for precursor lymphoid neoplasms. 5-year HN survival was 58.7%. The lowest 5-year survival rates were observed for acute myeloid leukemias (26.2%), 90+ years (10.3%), males (57.4%), non-Hispanic Blacks (56.3%), widowed (34.5%), non-metropolitan residents (54.0%), and <$40,000 AHI (50.1%).
CONCLUSIONS: The study findings showed a high HN burden. Most HN subtypes demonstrated increasing incidence and mortality trends. The lowest 5-year survival was observed for acute myeloid leukemias, with survival chances of approximately 1 in 4 patients. These results should be a compelling reason to accelerate the discovery and approval of new treatments.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH246
Topic
Epidemiology & Public Health, Real World Data & Information Systems
Disease
Oncology